Geron (NASDAQ:GERN) Issues Earnings Results

Geron (NASDAQ:GERN) issued its quarterly earnings results on Wednesday. The biopharmaceutical company reported ($0.01) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.03) by $0.02, Zacks reports. Geron had a negative return on equity of 28.86% and a negative net margin of 46.65%.

Here are the key takeaways from Geron’s conference call:

• Rytelo Q1 net revenue was $61.8M (up 31% YoY, 8% QoQ), demand grew ~6% QoQ, footprint expanded to ~1,450 prescribing accounts, and management says it is on track for 2026 revenue guidance of $220–$240M.
• The phase III IMpactMF trial is fully enrolled with an interim overall‑survival event trigger expected in H2 2026, and management says a positive interim could materially strengthen imetelstat’s disease‑modifying profile and support broader MDS uptake.
• Geron is evaluating multiple go‑to‑market models for Europe (not pursuing a large internal build‑out), is conducting HTA/pricing work, and expects to announce its European commercial plan by year‑end.
• Gross‑to‑net deductions rose to 21% (from 13% a year ago) due to increased 340B utilization and GPO contracting and are expected to remain in the low‑to‑mid 20s for 2026, which pressures realized net revenue.
• Total operating expenses declined ~9% YoY to $50.4M in Q1 and management reiterated Opex guidance of $230–$240M; cash was ~$341M at quarter end after planned bonus, severance and CMC investments.

Geron Trading Down 4.2%

Shares of NASDAQ GERN traded down $0.07 during midday trading on Wednesday, hitting $1.58. The stock had a trading volume of 21,455,098 shares, compared to its average volume of 15,212,574. The company has a market capitalization of $1.01 billion, a price-to-earnings ratio of -12.15 and a beta of 0.68. Geron has a 1-year low of $1.04 and a 1-year high of $2.01. The company has a quick ratio of 3.62, a current ratio of 4.66 and a debt-to-equity ratio of 0.53. The company has a fifty day moving average price of $1.60 and a 200 day moving average price of $1.43.

Hedge Funds Weigh In On Geron

Hedge funds and other institutional investors have recently modified their holdings of the company. Caitong International Asset Management Co. Ltd lifted its stake in shares of Geron by 3,307.6% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 25,148 shares of the biopharmaceutical company’s stock valued at $33,000 after purchasing an additional 24,410 shares in the last quarter. Amundi acquired a new position in Geron during the 4th quarter worth approximately $38,000. Franklin Resources Inc. acquired a new position in Geron during the 3rd quarter worth approximately $45,000. Cibc World Markets Corp acquired a new position in Geron during the 4th quarter worth approximately $48,000. Finally, Atom Investors LP lifted its position in Geron by 137.0% during the 4th quarter. Atom Investors LP now owns 37,341 shares of the biopharmaceutical company’s stock worth $49,000 after acquiring an additional 21,588 shares in the last quarter. 73.71% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on GERN shares. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Geron in a research note on Monday, April 27th. TD Cowen reaffirmed a “buy” rating on shares of Geron in a research note on Thursday, January 29th. Two investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, Geron currently has an average rating of “Hold” and an average price target of $2.17.

Geron Company Profile

Geron Corporation (NASDAQ: GERN) is a clinical-stage biotechnology company dedicated to developing and commercializing novel treatments that target telomerase, an enzyme critical to cancer cell immortality. The company’s research is focused on hematologic malignancies and solid tumors, with a pipeline designed to address diseases that have historically had limited therapeutic options.

The lead product candidate, imetelstat, is a first-in-class telomerase inhibitor currently in Phase II and Phase III clinical trials for myelofibrosis and myelodysplastic syndromes.